• Skip to main content
  • Skip to after header navigation
  • Skip to site footer
  • HOME
  • Start here
  • About Michael Alvear
    • My Mission Statement
    • Contact Me
    • My Journey
    • Medical Disclaimer
    • Privacy Policy
    • Medical Review Standards: Expert Transparency & Editorial Process
  • Ketamine Therapy Basics
    • What Is it?
    • How Does It Work?
    • Side Effects
    • Are You a Candidate?
    • Which Type of Ketamine Treatment Should You Choose?
    • The Complete Guide To Oral Ketamine [2025]
    • IV Ketamine vs. Spravato: Which Is Better?
    • Inside Ketamine Clinics
    • Integration makes ketamine work
  • How to Get a Free Ride to Your Medical Appointments
  • Effectiveness & Comparisons
    • Up to 70% Remission Rates
    • Works Faster Than Other Treatments
    • How It’s Different Than Other Treatments
    • IV Ketamine vs. Nasal Spray
    • Ketamine vs. SSRIs: Which Works Best?
    • Research Resource Hub
  • Cost & Insurance
    • Does Insurance Cover Spravato?
    • How Much Does Spravato Cost With & Without Insurance? 2025 Cost Guide + Calculator
    • Guide to Costs & Insurance Coverage
    • Spravato Costs with Insurance
    • IV Ketamine vs. Spravato: How Many Sessions You’ll Need To End or Substantially Reduce Depression
    • How Much Does Ketamine Therapy Cost? What You’ll Pay for IV, Spravato, and Injections
    • Does Insurance Cover Ketamine Therapy
  • Celebrity Deaths & Misuse
    • Will Musk Do To Ketamine What He Did To Tesla?
    • Ketamine and Matthew Perry’s Death
    • First Matthew Perry, Now The Vivienne. The Ketamine Panic Is Here
  • Blog
  • Find Nearest Clinic
ketamine therapy for depression

Does Insurance Cover IV, Injection & Oral/Sublingual Ketamine?

Michael Alvear

By Michael Alvear, Health Author & Independent Researcher

My research is published on these scholarly platforms:

Scholarly Platforms

Last Updated: December 5, 2025

Insurance Coverage of IV, Injection, and Oral Ketamine for Depression

Coverage and non-coverage patterns among 18 commercial insurers.

3 of 18
Only 16.7% of major commercial insurers cover IV ketamine therapy for depression. None cover IM injections or oral/sublingual ketamine.

Insurer IV Injection Oral Policy Documentation
Kaiser Permanente NO NO Not Stated Kaiser WA ketamine clinical criteria (PDF)
HCSC (BCBS IL/TX/NM/OK/MT) NO NO* NO* BCBSIL Blue Review article – Fighting Fraud (May 2021)
UnitedHealthcare NO NO* NO* UnitedHealthcare Ketalar/Ketamine Policy
Anthem Blue Cross Blue Shield (various states) NO NO NO* Anthem Ketamine Policy
Aetna NO NO NO Aetna Clinical Policy Bulletin 0938
Florida Blue Not Stated Not Stated Not Stated Florida Blue MCG medical policy 09-J3000-37
Cigna Healthcare NO NO* NO* Cigna pharmacy coverage policy PH-1701 – unassigned medical injectable (PDF)
Ambetter (various states) YES NO* NO* Centene / Health Net ketamine (Ketalar) policy CP.PMN.296 (PDF)
Highmark Blue Cross Blue Shield YES NO* NO* Highmark commercial medical policy I-32-012 – intravenous anesthetics for off-label indications
Blue Cross NC NO NO* NO* Blue Cross NC commercial medical policy – intravenous anesthetics for the treatment of chronic pain and psychiatric disorders
Blue Cross Blue Shield of Massachusetts YES NO* NO* Blue Cross MA medical policy – Spravato (esketamine) and intravenous ketamine for mental health conditions (PDF)
Blue Cross Blue Shield of Michigan NO NO* NO* BCBSM medical policy document 2087622 (PDF)
Horizon Blue Cross Blue Shield of New Jersey NO NO* NO* Horizon BCBSNJ medical policy – intravenous anesthetics for chronic pain and depression
Independence Blue Cross NO NO* NO* Independence Blue Cross commercial medical policy – intravenous ketamine (experimental/investigational)
BlueCross BlueShield of Tennessee NO NO* NO* Blue Cross Tennessee medical policy – intravenous ketamine (experimental/investigational)
Harvard Pilgrim & Tufts Health Plan (Commercial) NO NO* NO* Harvard Pilgrim medical policy – intravenous ketamine (experimental/investigational)
Humana (commercial book only–no medicare) Not Stated Not Stated Not Stated Humana medical coverage policies portal
Molina Healthcare NO NO* NO* Molina Healthcare Iowa – Spravato (esketamine) nasal spray prior authorization form (PDF)

Understanding Coverage Status

YES

The insurer has a written policy that explicitly covers that ketamine route for depression / treatment-resistant depression when specific criteria are met (often with prior authorization and strict rules).

NO

The insurer has a written policy that explicitly classifies that ketamine route for depression as not covered (e.g., “not medically necessary,” “experimental,” or “investigational”).

NO*

The policy does not literally spell out “no” for this route, but the overall policy makes it effectively a no in real life. We use NO* in two situations:

  1. The insurer explicitly says IV ketamine for depression is not covered, and there is no separate policy that covers injection or oral ketamine for depression; or
  2. The insurer only covers IV ketamine inside a very narrow carve-out (for example, in-clinic IV Ketalar for TRD with strict criteria) and never mentions injection or oral ketamine at all.

In both cases, it is highly unlikely that a plan would secretly cover injection or oral ketamine for depression when it either refuses IV or barely covers IV under a tight program.

For patients: Treat NO* as “This route is almost certainly not covered; we just don’t have a sentence in the policy that says it in so many words.”

Not Stated

We could not find any clear public policy language about this route for depression from this insurer. In practice, that usually means:

  • There is no established benefit the plan is promising for this treatment; and
  • Claims are very likely to be denied unless a specific exception or custom arrangement is made.

Important: We keep “Not Stated” here only to be transparent that we don’t have an actual PDF line to quote, not because coverage is likely. If your insurer has “Not Stated” in this column, you should still assume it is not covered unless you get something different in writing from the plan.

Important Limits of This Table

  • This table only looks at ketamine used to treat depression (usually treatment-resistant depression). It does not show coverage for anesthesia, pain management, or other uses.
  • Spravato® (esketamine nasal spray) is handled under separate policies. Many insurers that refuse IV / injection / oral ketamine do cover Spravato® when criteria are met—that’s outside the scope of these columns.
  • These entries summarize public insurer policy documents, not any one person’s specific plan. Coverage can vary by employer, state, network, and plan design, and policies change over time.
  • Before starting treatment or assuming a bill will be covered, patients should confirm benefits directly with their insurer or have the clinic run a prior authorization / benefits check for their exact plan.

Data compiled from publicly available insurance policy documents. Coverage policies subject to change.
Always verify current coverage status directly with your insurance provider before pursuing treatment.

Remission Roadmap PDF
Get My Remission Roadmap Today
Find out everything you need to do before, during, and after each session
This Preparation System Helped End My Depression
Inside You’ll Discover:
✓ How to Use the 48-Hour “Golden Window” of Neuroplasticity so Progress Doesn’t Fade
✓ A “Go-Bag” Checklist so You Never Show Up Unprepared Again
✓ How I Kept Drinking From Sabotaging My Ketamine Treatment
✓ Links to Session-Tested Playlists so You’re Not Guessing About Music
✓ How to Work With a Psychedelic Therapist so Each Session Moves You Closer to Remission

Get My Remission Roadmap

Downloads as PDF • 42 pages

Ketamine Coverage by Insurance Company

Click your insurer to see coverage details

Insurer Market Share Members
Kaiser Permanente 13% 18,183,921
HCSC (BCBS IL/TX/NM/OK/MT) 8% 10,910,353
UnitedHealthcare 8% 11,190,105
Anthem Blue Cross Blue Shield 6% 8,252,703
Aetna 5% 6,993,816
Florida Blue 4% 5,315,300
Cigna Healthcare 4% 5,874,805
Ambetter 3% 4,056,413
Highmark Blue Cross Blue Shield 2% 2,517,774
Blue Cross NC 2% 2,238,021
Blue Cross Blue Shield of Massachusetts 1% 1,678,516
Blue Cross Blue Shield of Michigan 1% 1,818,392
Horizon Blue Cross Blue Shield of New Jersey 1% 1,678,516
Independence Blue Cross 1% 1,258,887
BlueCross BlueShield of Tennessee 1% 1,119,011
Harvard Pilgrim & Tufts Health Plan 1% 979,134
Humana 1% 1,258,887
Molina Healthcare 1% 559,505

NEXT ON THE INSURANCE FRONT:


▶ Does Insurance Cover Spravato?


▶ Does Medicare Cover Spravato?


▶ Does Medicaid Cover Spravato?


▶ How To Get Spravato Covered By Insurance


▶ Why Insurance Won’t Cover IV Ketamine


▶ Does Medicaid Cover Spravato?


▶ Guide To Getting Medicare To Approve Spravato


▶ Guide To Getting Medicaid To Approve Spravato


▶ How Much Does Ketamine Therapy Cost With or Without Insurance?


▶ How Much Does Ketamine Therapy Cost With or Without Insurance?


▶ Does Insurance Cover Ketamine Therapy?

Does Kaiser Permanente Cover IV, Injection and Oral Ketamine?

Bottom line: NO – Kaiser Permanente does not cover IV, injection, or oral ketamine for depression.

The ketamine policy treats ketamine given by intranasal, intravenous, or subcutaneous routes as experimental for psychiatric conditions and lists depression as a non-covered diagnosis. It does not spell out any coverage criteria for oral or sublingual ketamine.

Route Covered for depression? What Kaiser’s policy says*
IV ketamine infusions NO

Classified as experimental / non-covered.
Ketamine given intravenously is grouped with intranasal and subcutaneous ketamine and considered experimental and investigational for psychiatric diagnoses, with depression listed as a non-covered diagnosis.
Injection ketamine (IM / subcutaneous) NO

Classified as experimental / non-covered.
Subcutaneous ketamine for psychiatric conditions, including depression, falls under the same experimental and investigational statement and is treated as a non-covered service.
Oral / sublingual ketamine NOT STATED

Coverage very unlikely.
The ketamine clinical review criteria do not address oral or sublingual ketamine for depression at all. In practice, when IV ketamine is explicitly denied, oral ketamine is almost never covered.

*Based on Kaiser Foundation Health Plan ketamine clinical review criteria published in the document “Ketamine for the Treatment of Depression and Other Psychiatric Disorders”.

NOT COVERED

IV ketamine infusions

IV ketamine infusions for depression are not covered.

The ketamine clinical review criteria state that ketamine given intranasally, intravenously, or subcutaneously is considered experimental and investigational for psychiatric diagnoses, and depression is specifically listed as a non-covered diagnosis. That language is what clinics run into when they try to bill IV ketamine for depression.

What this means for you:

If you want IV ketamine for depression while covered by Kaiser, you should expect to pay a clinic’s cash rate. This is why you usually do not see Kaiser listed as in-network for IV ketamine programs.

NOT COVERED

Injection ketamine (IM / subcutaneous)

Injection-based ketamine for depression is not covered.

Subcutaneous ketamine is grouped with intranasal and intravenous ketamine in the same experimental and investigational statement, with depression treated as a non-covered diagnosis. Although the policy language highlights subcutaneous administration, in practice IM (intramuscular) programs are treated the same way when used for depression.

What this means for you:

Clinics offering IM or subcutaneous ketamine for depression generally cannot bill Kaiser as a covered medical benefit, so they quote out-of-pocket prices similar to IV ketamine.

NOT STATED

Oral / sublingual ketamine

Oral and sublingual ketamine for depression are not mentioned in the ketamine criteria, and coverage is very unlikely.

The ketamine clinical review criteria do not include any section on oral or sublingual ketamine for depression or other psychiatric diagnoses. There is no medical-necessity standard, no dosing guidance, and no indication that Kaiser intends to cover oral ketamine for depression.

What this means for you:

If a prescriber offers you oral or sublingual ketamine for depression while you are on a Kaiser plan, you should assume it will be an out-of-pocket treatment unless you receive a very clear, written confirmation of coverage from Kaiser.

Important fine print for Kaiser members

  • This summary is based on Kaiser Foundation Health Plan non-Medicare clinical review criteria for ketamine for depression and other psychiatric disorders, as published in the ketamine criteria document “Ketamine for the Treatment of Depression and Other Psychiatric Disorders” and the related clinical review criteria resources.
  • Kaiser notes that these clinical review criteria are tools used to administer plan benefits and do not offer medical advice or guarantee coverage; your actual contract and benefit documents control.
  • Benefits can vary by employer group and specific product. To confirm your own situation, check your Evidence of Coverage or benefit booklet and call the Member Services number on your ID card.

Does HCSC (BCBS IL/TX/NM/OK/MT) Cover IV, Injection and Oral Ketamine?

NO – HCSC (BCBS IL/TX/NM/OK/MT) does not cover IV, injection or oral ketamine.

The Blue Review article on ketamine infusion therapy describes intravenous ketamine infusions for psychiatric disorders as experimental, investigational and/or unproven, which is the language the plan uses for non-covered services. The newsletter references medical policy SUR702.016 for IV anesthetics, but public materials do not outline any coverage criteria for injection or oral ketamine for depression.

Route Covered for depression? What the policy says*
IV ketamine infusions NO

Classified as experimental, investigational and/or unproven and not treated as a covered benefit for depression.
IV ketamine infusions to treat psychiatric disorders are described as experimental, investigational and/or unproven, including cases involving chronic pain and other psychiatric conditions.
Injection ketamine (IM / subcutaneous) NOT STATED

Coverage very unlikely because IV ketamine for depression is already treated as experimental and non-covered.
Public materials focus on IV infusions and provide no specific language on intramuscular or subcutaneous ketamine for depression, leaving no clear published path to covered injection treatment.
Oral / sublingual ketamine NOT STATED

Coverage very unlikely because oral and sublingual ketamine are not addressed where IV ketamine is already treated as non-covered.
Public materials do not address oral or sublingual ketamine for depression, so when IV ketamine is treated as experimental and non-covered, oral ketamine is effectively cash-pay.

*Based on ketamine infusion information published for these Blue Cross and Blue Shield plans in the article “Blue Review – Fighting Fraud, Waste and Abuse: Ketamine Infusion Therapy (BCBSIL)”.

NOT COVERED

IV ketamine infusions

IV ketamine infusions for depression are not covered.

The clinical materials explain that intravenous ketamine infusions to treat psychiatric disorders are considered experimental, investigational and/or unproven, including cases involving chronic pain and other psychiatric conditions. In this language, “experimental and investigational” means the service is not treated as a covered benefit for depression.

What this means for you:

If you want IV ketamine for depression with this type of plan, you should expect clinics to bill you at their cash rate, and attempts to bill IV ketamine as a covered mental health service are likely to be denied.

NOT STATED

Injection ketamine (IM / subcutaneous)

Coverage for injection ketamine for depression is effectively treated as a no.

None of the linked public materials provide specific criteria for intramuscular or subcutaneous ketamine for depression. When an insurer has already labeled IV ketamine infusions for psychiatric disorders as experimental, investigational and unproven, clinics generally assume that off-label injection routes are treated the same way.

What this means for you:

If a clinic offers IM or subcutaneous ketamine for depression, it will almost always be a self-pay service, and you should not expect your mental health benefits to reimburse those sessions.

NOT STATED

Oral / sublingual ketamine

Oral and sublingual ketamine for depression are not addressed and are effectively cash-pay.

The Blue Review article and related medical policy resources do not mention oral or sublingual ketamine for depression at all. When IV ketamine has already been placed in an experimental and non-covered category for psychiatric indications, it is highly unlikely that oral formulations would be handled more favorably.

What this means for you:

If you pursue oral or sublingual ketamine through a clinic, you should assume you will be paying the clinic’s cash rate and cannot rely on your plan to cover the medication or associated visits.

Important fine print for HCSC (BCBS IL/TX/NM/OK/MT) members

  • This summary is based on ketamine infusion information from the Blue Review article “Blue Review – Fighting Fraud, Waste and Abuse: Ketamine Infusion Therapy (BCBSIL)”, the related Blue Review PDF newsletter, and the general medical policy index that references SUR702.016 for IV anesthetics.
  • These materials describe how the plan evaluates ketamine services but do not guarantee payment for any specific member, diagnosis, clinic, or claim.
  • Your actual benefits depend on your individual contract, so always review your Evidence of Coverage and call the Member Services number on your ID card before scheduling treatment.
  • HCSC and its affiliated Blue Cross and Blue Shield plans operate in multiple states and product lines, and Medicare, Medicaid, or other products may have different ketamine rules than those summarized here.

Does UnitedHealthcare Cover IV, Injection and Oral Ketamine?

NO – UnitedHealthcare does not cover IV, injection or oral ketamine.

The commercial Ketalar/Spravato medical benefit drug policy classifies ketamine injection as investigational and not medically necessary for psychiatric disorders including depression. The coverage rationale treats ketamine injection for conditions such as depression, bipolar disorder, and posttraumatic stress disorder as not proven or medically necessary, and the policy does not spell out any coverage criteria for oral or sublingual ketamine for depression.

Route Covered for depression? What the policy says*
IV ketamine infusions NO

Classified as investigational and not medically necessary for psychiatric disorders including depression.
Coverage rationale states that ketamine injection is investigational, and therefore not proven or medically necessary for psychiatric disorders, including depression and other listed conditions.
Injection ketamine (IM / subcutaneous) NO

Same investigational and not medically necessary determination applies to ketamine injection given by IV or IM routes for psychiatric indications.
The policy explains that the ketamine injection criteria apply whether the drug is used by IV or IM routes for psychiatric disorders, so injection ketamine for depression is treated as non-covered.
Oral / sublingual ketamine NOT STATED

Coverage very unlikely because oral and sublingual ketamine are not discussed where ketamine injection is already denied for depression.
Oral or sublingual ketamine is not discussed; the policy only addresses ketamine injection (Ketalar) and Spravato nasal spray, leaving oral ketamine effectively in the cash-pay category for depression.

*Based on UnitedHealthcare commercial Ketalar/Spravato medical benefit drug policy published in the document “Commercial – national Ketalar/Spravato medical benefit drug policy”.

NOT COVERED

IV ketamine infusions

IV ketamine infusions for depression are not covered.

The coverage rationale for ketamine injection states that the drug is investigational and therefore not proven or medically necessary for psychiatric disorders, including depression, bipolar disorder, and posttraumatic stress disorder. When a service is labeled investigational and not medically necessary in this way, it is not treated as a covered benefit for depression.

What this means for you:

If you pursue IV ketamine infusions for depression, you should expect clinics to treat them as a self-pay service, and claims billed to your plan are likely to be denied.

NOT COVERED

Injection ketamine (IM / subcutaneous)

Injection ketamine for depression is not covered.

The Ketalar/Spravato policy explains that the ketamine injection criteria apply whether the drug is given by IV or IM routes for psychiatric indications. Because ketamine injection is classified as investigational and not medically necessary for psychiatric disorders including depression, clinics treat IM or subcutaneous ketamine for depression as non-covered as well.

What this means for you:

If a clinic offers IM or subcutaneous ketamine for depression, it will almost always be a cash-pay service rather than something your plan reimburses as a mental health benefit.

NOT STATED

Oral / sublingual ketamine

Oral and sublingual ketamine for depression are not addressed and effectively treated as cash-pay.

The commercial Ketalar/Spravato policy does not discuss oral or sublingual ketamine for depression and focuses only on ketamine injection and Spravato nasal spray. When an insurer already denies ketamine injection for psychiatric disorders as investigational and not medically necessary, it is highly unlikely to cover off-label oral ketamine for depression.

What this means for you:

If you work with a clinic that prescribes oral or sublingual ketamine, you should assume you will be paying the clinic’s cash rate and cannot rely on your plan to cover the medication or associated visits.

Important fine print for UnitedHealthcare members

  • This summary is based on the UnitedHealthcare commercial Ketalar/Spravato medical benefit drug policy and related materials, including the policy document “Commercial – national Ketalar/Spravato medical benefit drug policy”, the commercial medical and drug policy index, and the commercial medical policy update bulletin.
  • These materials describe how the plan evaluates ketamine services but do not guarantee payment for any specific member, diagnosis, clinic, or claim.
  • Your actual benefits depend on your individual contract, so always review your Evidence of Coverage and call the Member Services number on your ID card before scheduling treatment.
  • UnitedHealthcare administers multiple product lines, and employer plans, Medicare, Medicaid, or other products may have different ketamine rules than those summarized here.

Anthem Blue Cross Blue Shield: IV, Injection, and Oral Ketamine Coverage for Depression

NO – Anthem Blue Cross Blue Shield does not cover IV, injection or oral ketamine.

The CarelonRx ketamine injection clinical criteria limit approval of Ketalar to anesthesia and certain acute pain indications. For all other indications, including major depressive disorder and other psychiatric conditions, ketamine injection is described as a drug that may not be approved, and the document does not outline any coverage criteria for oral or sublingual ketamine for depression.

Route Covered for depression? What the policy says*
IV ketamine infusions NO

Not approved for major depressive disorder or other psychiatric indications.
Ketalar (ketamine injection) may not be approved when criteria for anesthesia or acute pain are not met and for other indications, including major depressive disorder and other psychiatric disorders.
Injection ketamine (IM / subcutaneous) NO

Same “may not be approved” determination applies to ketamine injection given by IV or IM routes for psychiatric indications.
The clinical criteria explain that the Ketalar limits apply to ketamine injection administered by IV or IM routes, and list major depressive disorder and other psychiatric indications among those that may not be approved.
Oral / sublingual ketamine NOT STATED

Coverage very unlikely because oral and sublingual ketamine are not addressed where ketamine injection is already not approved for depression.
The clinical criteria document is limited to Ketalar (ketamine injection) and do not address oral or sublingual ketamine products for depression, leaving these routes effectively in the cash-pay category.

*Based on CarelonRx ketamine injection clinical criteria used for Anthem commercial plans, as published in the document “Clinical Criteria – Ketalar (ketamine injection)”.

NOT COVERED

IV ketamine infusions

IV ketamine infusions for depression are not covered.

The CarelonRx criteria restrict Ketalar approval to anesthesia and selected acute pain situations. They state that ketamine injection may not be approved when criteria for anesthesia or acute pain are not met and for all other indications, including major depressive disorder and other psychiatric disorders. Clinics interpret this as a clear non-coverage stance for IV ketamine for depression.

What this means for you:

If you seek IV ketamine infusions for depression, you should expect clinics to treat them as a self-pay service, and claims billed to your plan are likely to be denied.

NOT COVERED

Injection ketamine (IM / subcutaneous)

Injection ketamine for depression is not covered.

The same CarelonRx clinical criteria apply to Ketalar whether it is administered by IV or IM routes for psychiatric indications. Because major depressive disorder and related conditions appear on the list of indications that may not be approved, injection ketamine for depression is treated as not medically necessary and not approvable under these criteria.

What this means for you:

If a clinic offers IM or subcutaneous ketamine for depression, it will almost always be a cash-pay service, and you should not expect your plan to reimburse those treatments as a mental health benefit.

NOT STATED

Oral / sublingual ketamine

Oral and sublingual ketamine for depression are not addressed and are effectively cash-pay.

The CarelonRx document is written specifically for Ketalar (ketamine injection) and does not discuss any oral or sublingual ketamine products for depression. When an insurer already refuses ketamine injection for psychiatric indications, it is highly unlikely to treat off-label oral ketamine more favorably.

What this means for you:

If you work with a clinic that prescribes oral or sublingual ketamine, you should assume you will be paying the clinic’s cash rate and cannot rely on your plan to cover the medication or associated visits.

Important fine print for Anthem Blue Cross Blue Shield members

  • This summary is based on CarelonRx ketamine injection clinical criteria used for Anthem commercial plans, including the document “Clinical Criteria – Ketalar (ketamine injection)”, the CarelonRx clinical criteria index, and the Anthem pharmacy clinical criteria page.
  • These criteria describe how ketamine injection requests are evaluated but do not guarantee payment for any specific member, diagnosis, clinic, or claim.
  • Your actual benefits depend on your individual contract, so always review your Evidence of Coverage and call the Member Services number on your ID card before scheduling treatment.
  • Anthem operates in multiple states and product lines, and employer plans, Medicare, Medicaid, or other products may have different ketamine rules than those summarized here.

Does Aetna Cover IV, Injection and Oral Ketamine?

NO – Aetna does not cover IV, injection or oral ketamine.

The clinical policy bulletin on ketamine for depression explains that Aetna considers ketamine given intramuscularly, intranasally, intravenously, orally, or subcutaneously experimental, investigational, or unproven for depression. In this policy language, a service labeled experimental or unproven is not treated as a covered benefit for depressive disorders.

Route Covered for depression? What the policy says*
IV ketamine infusions NO

Classified as experimental, investigational or unproven for depression.
The bulletin states that Aetna considers ketamine given intravenously, as well as by other routes, experimental, investigational, or unproven for depression, which signals non-coverage.
Injection ketamine (IM / subcutaneous) NO

Same experimental and investigational determination applies to injection ketamine for depression.
The same policy statement covers intramuscular and subcutaneous ketamine and considers these routes experimental, investigational, or unproven for depression.
Oral / sublingual ketamine NO

Also classified as experimental, investigational or unproven for depression.
The bulletin explains that oral ketamine is experimental, investigational, or unproven for depression, so oral and sublingual products are not treated as covered benefits.

*Based on Aetna clinical policy bulletin “Ketamine for the Treatment of Depression and Other Selected Indications (CPB 0938)”.

NOT COVERED

IV ketamine infusions

IV ketamine infusions for depression are not covered.

The ketamine bulletin explains that Aetna considers ketamine given intravenously, along with other routes, experimental, investigational, or unproven for depression. When a service is placed in this category, there is no standard path for it to be treated as a covered benefit for depressive disorders.

What this means for you:

If you pursue IV ketamine infusions for depression, you should expect clinics to treat them as a self-pay service, and claims sent to your plan are likely to be denied as experimental or investigational.

NOT COVERED

Injection ketamine (IM / subcutaneous)

Injection ketamine for depression is not covered.

The same policy language that applies to IV ketamine also applies to intramuscular and subcutaneous routes, because the bulletin groups these routes together. By labeling ketamine injection experimental, investigational, or unproven for depression, the policy signals that these treatments are not medically necessary under the plan’s standards.

What this means for you:

If a clinic offers IM or subcutaneous ketamine for depression, it will almost always be a cash-pay service, and you should not expect your plan to reimburse those injections as a mental health benefit.

NOT COVERED

Oral / sublingual ketamine

Oral and sublingual ketamine for depression are not covered.

The bulletin explicitly includes oral ketamine in the list of routes Aetna considers experimental, investigational, or unproven for depression. When a route is described this way, there is no published route to having it approved as a covered benefit for depressive disorders.

What this means for you:

If you work with a clinic that prescribes oral or sublingual ketamine for depression, you should assume you will be paying the clinic’s cash rate and cannot rely on your plan to cover the medication or related visits.

Important fine print for Aetna members

  • This summary is based on Aetna clinical policy bulletins including “Ketamine for the Treatment of Depression and Other Selected Indications (CPB 0938)”, the related bulletin CPB 0950, and the general Aetna medical clinical policy bulletin index.
  • These bulletins describe how Aetna evaluates ketamine services but do not guarantee payment for any specific member, diagnosis, clinic, or claim.
  • Your actual benefits depend on your individual contract, so always review your Evidence of Coverage and call the Member Services number on your ID card before scheduling treatment.
  • Aetna offers multiple product lines, and employer plans, Medicare, Medicaid, or other products may have different ketamine rules than those summarized here.

Does Florida Blue Cover IV, Injection and Oral Ketamine?

Coverage for IV, injection and oral ketamine is not stated in Florida Blue policies and usually functions like a no; only Spravato nasal spray is clearly defined as a ketamine-based depression treatment.

The Spravato nasal spray medical coverage guideline is the only Florida Blue policy that addresses a ketamine-based treatment for depression, and it focuses solely on intranasal esketamine. The guideline notes that Spravato is for nasal use only and that the patient is not receiving concomitant ketamine therapy, without outlining any coverage position for IV, intramuscular, subcutaneous, oral, or sublingual ketamine.

Route Covered for depression? What the policy says*
IV ketamine infusions NOT STATED

Coverage very unlikely; only Spravato nasal spray is defined as a ketamine-based depression treatment.
The Spravato guideline focuses on intranasal esketamine and states that the patient is not receiving concomitant ketamine therapy, with no separate IV ketamine coverage position or criteria.
Injection ketamine (IM / subcutaneous) NOT STATED

Coverage very unlikely; policy language defines only intranasal Spravato and does not carve out IM or subcutaneous ketamine for depression.
The policy notes that Spravato is for nasal use only and prohibits concomitant ketamine therapy, but intramuscular or subcutaneous ketamine are not otherwise addressed as covered treatments for depression.
Oral / sublingual ketamine NOT STATED

Coverage very unlikely; oral and sublingual ketamine are not mentioned where only nasal Spravato is defined.
The guideline states that Spravato is for nasal use only, and no oral or sublingual ketamine terms appear in the policy text, leaving these routes without any published coverage pathway.

*Based on Florida Blue Spravato nasal spray coverage materials, including the medical coverage guideline “Spravato (esketamine) Nasal Spray – Medical Coverage Guideline (PH-0481/09-J3000-37)”.

NOT STATED

IV ketamine infusions

IV ketamine infusions for depression are not mentioned in public policies and function like a no in practice.

The Spravato coverage guideline is written around intranasal esketamine as the defined ketamine-based option for treatment-resistant depression. It specifies that Spravato is for nasal use only and that the patient is not receiving concomitant ketamine therapy, but it does not describe any circumstances where IV ketamine infusions for depression would be considered a covered benefit.

What this means for you:

If you pursue IV ketamine infusions for depression, clinics will almost always treat them as self-pay, and attempts to bill them as a covered mental health service are very likely to be denied.

NOT STATED

Injection ketamine (IM / subcutaneous)

Injection ketamine for depression is not addressed and effectively treated as non-covered.

The same Spravato guideline does not create any separate criteria for intramuscular or subcutaneous ketamine, even though it clearly defines nasal Spravato dosing and monitoring requirements. By limiting ketamine-based coverage to intranasal esketamine and prohibiting concomitant ketamine therapy, the policy leaves no defined path for IM or subcutaneous ketamine to be approved for depression.

What this means for you:

If a clinic offers IM or subcutaneous ketamine for depression, you should assume those sessions will be cash-pay and not reimbursed through your standard mental health benefits.

NOT STATED

Oral / sublingual ketamine

Oral and sublingual ketamine for depression are not mentioned and function like cash-pay treatments.

The Spravato medical coverage guideline repeatedly emphasizes that the product is for nasal use only and does not reference any oral or sublingual ketamine products for depression. When the only defined ketamine-based benefit is Spravato nasal spray, there is no indication that off-label oral ketamine would be handled as a covered service.

What this means for you:

If you work with a clinic that prescribes oral or sublingual ketamine, you should expect to pay the clinic’s cash rate and not rely on your plan to cover the medication or associated visits.

Important fine print for Florida Blue members

  • This summary is based on Florida Blue Spravato nasal spray materials, including the medical coverage guideline “Spravato (esketamine) Nasal Spray – Medical Coverage Guideline (PH-0481/09-J3000-37)”, the policy page Spravato (esketamine) Nasal Spray – Medical Policies, and the broader medical policies and coverage guidelines index.
  • These documents describe how Spravato requests are evaluated but do not guarantee payment for any specific member, diagnosis, clinic, or claim.
  • Your actual benefits depend on your individual contract, so always review your Evidence of Coverage and call the Member Services number on your ID card before scheduling treatment.
  • Florida Blue and related plans may have different rules across product lines, and separate policies for Spravato, IV ketamine, or other treatments may apply to Medicare, Medicaid, or employer-specific benefits.

Does Cigna Healthcare Cover IV, Injection and Oral Ketamine?

NO – Cigna Healthcare does not cover IV, injection or oral ketamine.

The outpatient Ketalar coverage criteria state that ketamine intravenous use for any outpatient indication, including major depressive disorder, is considered not medically necessary. Publicly available materials do not describe coverage criteria for other ketamine injection routes or for oral or sublingual ketamine for depression, so these routes function like cash-pay options in practice.

Route Covered for depression? What the policy says*
IV ketamine infusions NO

Outpatient IV ketamine for depression is considered not medically necessary.
Coverage position language states that Ketalar for any outpatient use is considered not medically necessary, including major depressive disorder and other depressive indications.
Injection ketamine (IM / subcutaneous) NOT STATED

Coverage very unlikely; only IV Ketalar outpatient criteria are defined for depression.
The Ketalar outpatient policy focuses on intravenous use and does not spell out separate coverage criteria for intramuscular or subcutaneous ketamine for depression, leaving no clear path to approval.
Oral / sublingual ketamine NOT STATED

Coverage very unlikely; oral and sublingual ketamine are not addressed where IV Ketalar is already considered not medically necessary.
The outpatient Ketalar coverage position does not discuss oral or sublingual ketamine for depression, so these routes are effectively treated as self-pay options.

*Based on Cigna Healthcare pharmacy coverage materials for Ketalar, including the document “Unassigned Drug Code Outpatient Medical Precertification – Ketalar (ketamine intravenous)”.

NOT COVERED

IV ketamine infusions

IV ketamine infusions for depression are not covered.

The Ketalar outpatient coverage position explains that ketamine intravenous use for any outpatient indication is considered not medically necessary, and it specifically includes major depressive disorder in that determination. When a service is labeled not medically necessary in this way, there is no standard path for it to be treated as a covered benefit for depression.

What this means for you:

If you pursue IV ketamine infusions for depression, clinics will almost always treat them as self-pay, and claims sent to your plan are very likely to be denied as not medically necessary.

NOT STATED

Injection ketamine (IM / subcutaneous)

Coverage for injection ketamine for depression is not stated and functions like a no.

The available coverage materials focus on Ketalar given intravenously and do not create a separate coverage pathway for intramuscular or subcutaneous ketamine for depression. When the same product is already considered not medically necessary for outpatient IV use in major depressive disorder, clinics generally assume that off-label IM or subcutaneous use for depression will be treated the same way.

What this means for you:

If a clinic offers IM or subcutaneous ketamine for depression, you should expect those sessions to be cash-pay and not reimbursed as a covered mental health benefit.

NOT STATED

Oral / sublingual ketamine

Oral and sublingual ketamine for depression are not addressed and effectively treated as cash-pay.

The Ketalar outpatient policy does not discuss oral or sublingual ketamine for depression, and other publicly available materials focus on compounded medications in general or on esketamine nasal spray rather than oral ketamine. In this context, there is no published route for oral or sublingual ketamine to be treated as a covered benefit for depression.

What this means for you:

If you work with a clinic that prescribes oral or sublingual ketamine, you should assume you will be paying the clinic’s cash rate and not using your standard mental health benefits for the medication or associated visits.

Important fine print for Cigna Healthcare members

  • This summary is based on Cigna Healthcare pharmacy coverage policies, including the Ketalar coverage position in “Unassigned Drug Code Outpatient Medical Precertification – Ketalar (ketamine intravenous)”, the coverage criteria for compounded medications, and the esketamine nasal spray coverage criteria.
  • These documents describe how requests for Ketalar and related therapies are evaluated but do not guarantee payment for any specific member, diagnosis, clinic, or claim.
  • Your actual benefits depend on your individual contract, so always review your Evidence of Coverage and call the Member Services number on your ID card before scheduling treatment.
  • Cigna Healthcare offers multiple product lines, and employer plans, Medicare, Medicaid, or other products may have different ketamine rules than those summarized here.

Does Ambetter Cover IV, Injection and Oral Ketamine?

YES, BUT ONLY IV KETAMINE – Ambetter may cover IV ketamine infusions for depression with strict prior authorization; injection and oral ketamine are not addressed and usually function like a no.

The Ketalar clinical policy for Ambetter lays out criteria for intravenous ketamine in treatment-resistant depression and major depressive disorder, requiring IV administration plus multiple failed antidepressant treatments. The same documents do not create any explicit coverage pathway for intramuscular, subcutaneous, oral, or sublingual ketamine for depression, so those routes are left undefined.

Route Covered for depression? What the policy says*
IV ketamine infusions YES, WITH PRIOR AUTHORIZATION

Approved only for treatment-resistant depression and major depressive disorder when strict criteria are met.
Clinical criteria state that for treatment-resistant depression and major depressive disorder all of the following must apply: the request is for intravenous ketamine and there has been failure of two antidepressants and one augmentation therapy.
Injection ketamine (IM / subcutaneous) NOT STATED

Coverage very unlikely; only IV ketamine is defined for depression.
The Ketalar policy describes criteria specifically for intravenous ketamine in treatment-resistant depression and major depressive disorder and does not spell out any approval criteria for intramuscular or subcutaneous ketamine.
Oral / sublingual ketamine NOT STATED

Coverage very unlikely; oral and sublingual ketamine are not mentioned in the policy text.
The clinical policy focuses on Ketalar injection and does not address any oral or sublingual ketamine products for depression, leaving these routes without a published coverage pathway.

*Based on Ambetter clinical policy “Clinical Policy: Ketamine (Ketalar) – CP.PMN.296”.

COVERED WITH PRIOR AUTH

IV ketamine infusions

IV ketamine infusions for depression may be covered with prior authorization when strict criteria are met.

The Ketalar policy explains that intravenous ketamine can be approved for treatment-resistant depression and major depressive disorder only when specific conditions are satisfied. These include that the request is for IV ketamine and that you have already failed at least two antidepressants plus one augmentation therapy. This is a narrow pathway aimed at people whose depression has not responded to standard medication strategies.

What this means for you:

If you are seeking IV ketamine for depression, a clinic that works with Ambetter may be able to obtain prior authorization when you clearly meet the treatment-resistant criteria, but coverage is not automatic and not all clinics participate with these plans.

NOT STATED

Injection ketamine (IM / subcutaneous)

Coverage for injection ketamine for depression is not stated and usually functions like a no.

The same policy that defines IV ketamine approval never carves out a separate role for intramuscular or subcutaneous ketamine in depression. Because the criteria are written specifically around intravenous administration for treatment-resistant depression, clinics generally assume that off-label IM or subcutaneous protocols for depression will not be approved under this policy.

What this means for you:

If a clinic offers IM or subcutaneous ketamine for depression, you should expect those sessions to be treated as cash-pay unless the clinic can show you very specific evidence that a prior authorization for your case has been granted.

NOT STATED

Oral / sublingual ketamine

Oral and sublingual ketamine for depression are not addressed and effectively treated as cash-pay.

The Ketalar clinical policy does not mention oral or sublingual ketamine products anywhere in its depression criteria. When only IV ketamine is defined for treatment-resistant depression and major depressive disorder, there is no indication that off-label oral ketamine would be handled as a covered mental health benefit.

What this means for you:

If you work with a clinic that prescribes oral or sublingual ketamine, you should assume you will be paying the clinic’s cash rate and cannot rely on your Ambetter plan to cover the medication or associated visits.

Important fine print for Ambetter members

  • This summary is based on Ambetter and Centene pharmacy policies, including “Clinical Policy: Ketamine (Ketalar) – CP.PMN.296”, the related ketamine policy at CP.PMN.199, and other materials in the Ambetter pharmacy policy library.
  • These criteria describe how requests for ketamine are evaluated but do not guarantee payment for any specific member, diagnosis, clinic, or claim.
  • Your actual benefits depend on your individual contract, so always review your Evidence of Coverage and call the Member Services number on your ID card before scheduling treatment.
  • Centene and Ambetter offer multiple products in different states, and Medicaid, marketplace, employer, or other plan designs may have ketamine rules that differ from what is summarized here.

Does Highmark Blue Cross Blue Shield Cover IV, Injection and Oral Ketamine?

YES, BUT ONLY IV KETAMINE – Highmark may cover IV ketamine infusions for depression with strict criteria, while injection and oral ketamine are not addressed and usually function like a no.

The Highmark intravenous anesthetics policy allows ketamine (Ketalar) to be considered medically necessary for treatment-resistant or major depressive disorder only when all policy criteria are met and states that ketamine not meeting those criteria is considered not medically necessary. The policy focuses on IV infusion and does not create separate coverage determinations for intramuscular, subcutaneous, oral, or sublingual ketamine for depression.

Route Covered for depression? What the policy says*
IV ketamine infusions YES, WITH PRIOR AUTHORIZATION

Medically necessary only for TRD/MDD when all criteria are met; otherwise not medically necessary.
The policy states that ketamine (Ketalar) may be considered medically necessary for adults when specified criteria are met and that ketamine not meeting those criteria is considered not medically necessary.
Injection ketamine (IM / subcutaneous) NOT STATED

Coverage very unlikely; depression criteria are written only for IV ketamine infusion.
The policy focuses on IV ketamine infusions and does not give a separate coverage determination for intramuscular ketamine; J3490 Ketalar is addressed as an IV anesthetic and IM use for depression is not discussed.
Oral / sublingual ketamine NOT STATED

Coverage very unlikely; oral and sublingual ketamine are not mentioned in the depression section.
The policy is written for IV anesthetics and does not mention oral or sublingual ketamine for depression, leaving these routes without any published coverage pathway.

*Based on Highmark commercial medical policy “Intravenous Anesthetics for Off-Label Indications (I-32-012)”, including the TRD/MDD section on ketamine (Ketalar).

COVERED WITH PRIOR AUTH

IV ketamine infusions

IV ketamine infusions for depression may be covered with prior authorization when strict criteria are met.

The policy explains that ketamine (Ketalar) may be considered medically necessary for adults with treatment-resistant or major depressive disorder when all listed criteria are satisfied and explicitly states that ketamine not meeting those criteria is considered not medically necessary. The approval pathway is narrow and tied to a specific TRD/MDD section rather than to general off-label use.

What this means for you:

If you are pursuing IV ketamine infusions for depression, a clinic that works with Highmark may be able to obtain prior authorization when you clearly meet the TRD/MDD criteria, but coverage is not automatic and any request that does not match the policy is likely to be denied.

NOT STATED

Injection ketamine (IM / subcutaneous)

Coverage for injection ketamine for depression is not stated and usually functions like a no.

The same policy is framed around IV anesthetics and addresses Ketalar under an IV infusion code, without carving out a separate role for intramuscular or subcutaneous ketamine in depression. When coverage criteria are written specifically for IV ketamine and no language supports IM ketamine for depressive disorders, clinics typically treat IM protocols as non-covered.

What this means for you:

If a clinic offers IM or subcutaneous ketamine for depression, you should expect those sessions to be cash-pay unless the clinic can show you a prior authorization approval for your specific case.

NOT STATED

Oral / sublingual ketamine

Oral and sublingual ketamine for depression are not addressed and effectively treated as cash-pay.

The intravenous anesthetics policy does not mention oral or sublingual ketamine for depression and focuses instead on IV agents used off-label for psychiatric indications. Without any policy language supporting oral ketamine for depressive disorders, there is no standard path for these formulations to be approved as covered benefits.

What this means for you:

If you work with a clinic that prescribes oral or sublingual ketamine, you should assume you will be paying the clinic’s cash rate and not relying on your Highmark plan to cover the medication or associated visits.

Important fine print for Highmark Blue Cross Blue Shield members

  • This summary is based on Highmark commercial medical policy “Intravenous Anesthetics for Off-Label Indications (I-32-012)”, including the section that addresses ketamine (Ketalar) for treatment-resistant and major depressive disorder.
  • The policy describes how requests for IV ketamine are evaluated but does not guarantee payment for any particular member, diagnosis, clinic, or claim.
  • Your actual benefits depend on your individual contract, so always review your Evidence of Coverage and call the Member Services number on your ID card before scheduling treatment.
  • Highmark and affiliated Blue Cross Blue Shield plans may have different rules across states and product lines, and Medicare, Medicaid, or employer-specific plans can use different criteria than those summarized here.

Does Blue Cross NC Cover IV, Injection and Oral Ketamine?

NO – Blue Cross NC does not cover IV, injection or oral ketamine.

The commercial medical policy on intravenous anesthetics states that IV anesthetics, including ketamine, for chronic pain and psychiatric disorders (including treatment-resistant depression) are considered investigational and not covered. The policy focuses on IV infusions and does not create any explicit coverage pathway for intramuscular, oral, or sublingual ketamine for depression.

Route Covered for depression? What the policy says*
IV ketamine infusions NO

Classified as investigational and not covered for chronic pain and psychiatric disorders, including treatment-resistant depression.
The policy explains that intravenous anesthetics for the treatment of chronic pain and psychiatric disorders are considered investigational for all applications and notes that the plan does not provide coverage for investigational services.
Injection ketamine (IM / subcutaneous) NOT STATED

Coverage very unlikely; depression language is written only for IV anesthetics.
The policy statement applies to IV anesthetics and does not give a separate coverage determination for intramuscular ketamine for depression, leaving IM and subcutaneous routes without a defined approval pathway.
Oral / sublingual ketamine NOT STATED

Coverage very unlikely; oral and sublingual ketamine are mentioned only in background, not as covered treatments.
The policy discusses test infusions and mentions oral ketamine in background material but does not make any explicit coverage decision for oral or sublingual ketamine in depression.

*Based on the Blue Cross NC commercial medical policy “Intravenous Anesthetics for the Treatment of Chronic Pain and Psychiatric Disorders”.

NOT COVERED

IV ketamine infusions

IV ketamine infusions for depression are not covered.

The medical policy classifies IV anesthetics, including ketamine, as investigational when used for chronic pain and psychiatric disorders such as treatment-resistant depression. It further explains that services considered investigational are not covered benefits, which puts IV ketamine for depression in the non-covered category.

What this means for you:

If you pursue IV ketamine infusions for depression, clinics will almost always treat them as self-pay, and claims sent to your plan are very likely to be denied as investigational and not covered.

NOT STATED

Injection ketamine (IM / subcutaneous)

Coverage for injection ketamine for depression is not stated and in practice functions like a no.

The same policy is written around IV anesthetics and does not provide any separate determination for intramuscular or subcutaneous ketamine in depression. When IV ketamine is already considered investigational and non-covered for psychiatric indications, clinics generally assume that off-label IM or subcutaneous protocols for depression will be treated the same way.

What this means for you:

If a clinic offers IM or subcutaneous ketamine for depression, you should expect those sessions to be cash-pay and not reimbursed as a standard mental health benefit.

NOT STATED

Oral / sublingual ketamine

Oral and sublingual ketamine for depression are not addressed and effectively treated as cash-pay.

The intravenous anesthetics policy touches on oral ketamine only in background discussion and does not set coverage criteria for oral or sublingual ketamine in depression. Without any supportive policy language, there is no published path for these formulations to be treated as covered benefits for depressive disorders.

What this means for you:

If you work with a clinic that prescribes oral or sublingual ketamine, you should assume you will be paying the clinic’s cash rate and not relying on your Blue Cross NC plan to cover the medication or associated visits.

Important fine print for Blue Cross NC members

  • This summary is based on the Blue Cross NC commercial medical policy “Intravenous Anesthetics for the Treatment of Chronic Pain and Psychiatric Disorders”, including sections that address ketamine as an IV anesthetic.
  • The policy describes how requests for IV anesthetics such as ketamine are evaluated but does not guarantee payment for any specific member, diagnosis, clinic, or claim.
  • Your actual benefits depend on your individual contract, so always review your Evidence of Coverage and call the Member Services number on your ID card before scheduling treatment.
  • Blue Cross NC and related plans may have different rules across products and funding arrangements, and separate criteria can apply to Medicare, Medicaid, or employer-specific plans.

Does Blue Cross Blue Shield of Massachusetts Cover IV, Injection and Oral Ketamine?

YES, BUT ONLY IV KETAMINE – Blue Cross Blue Shield of Massachusetts may cover IV ketamine infusions for depression with prior authorization; injection and oral ketamine are not addressed and usually function like a no.

The medical policy on esketamine nasal spray and intravenous ketamine explains that IV ketamine can be covered for treatment-resistant depression and certain mental health conditions when specific medical necessity criteria are met. The same materials focus on IV infusions and intranasal esketamine and do not create any explicit coverage pathway for intramuscular, oral, or sublingual ketamine for depression.

Route Covered for depression? What the policy says*
IV ketamine infusions YES, WITH PRIOR AUTHORIZATION

Medically necessary only when policy 087 criteria are met; otherwise not medically necessary.
The policy states that intravenous ketamine and intranasal esketamine share the same medical necessity criteria for treatment-resistant depression and other mental health conditions and that ketamine is covered only when those criteria are met.
Injection ketamine (IM / subcutaneous) NOT STATED

Coverage very unlikely; only IV infusions and intranasal esketamine are defined.
Public materials and billing guidance describe intravenous ketamine infusions and intranasal esketamine, and do not mention intramuscular ketamine as a covered option for depression.
Oral / sublingual ketamine NOT STATED

Coverage very unlikely; oral and sublingual ketamine are not referenced.
There is no explicit coverage position for oral or sublingual ketamine in the policy text, and any use would be off-label and not included in the medical necessity criteria.

*Based on Blue Cross Blue Shield of Massachusetts medical policy “Esketamine Nasal Spray (Spravato) and Intravenous Ketamine for Mental Health Conditions (Medical Policy 087)”.

COVERED WITH PRIOR AUTH

IV ketamine infusions

IV ketamine infusions for depression may be covered with prior authorization when strict criteria are met.

The medical policy explains that intravenous ketamine shares the same medical necessity criteria as intranasal esketamine for treatment-resistant depression and related mental health conditions. Coverage requires that all policy 087 criteria are satisfied, and ketamine that does not meet those criteria is considered not medically necessary.

What this means for you:

If you are seeking IV ketamine infusions for depression, a participating clinic may be able to obtain prior authorization when you clearly meet the treatment-resistant criteria, but coverage is not automatic and requests that fall outside the policy are likely to be denied.

NOT STATED

Injection ketamine (IM / subcutaneous)

Coverage for injection ketamine for depression is not stated and usually functions like a no.

The same policy and related billing guidance focus on IV ketamine infusions and intranasal esketamine, without carving out a separate role for intramuscular ketamine in depression. When coverage criteria are written only for IV ketamine, clinics generally assume that off-label IM or subcutaneous protocols for depression will not be approved.

What this means for you:

If a clinic offers IM or subcutaneous ketamine for depression, you should expect those sessions to be cash-pay unless the clinic can show you a specific prior authorization approval for your case.

NOT STATED

Oral / sublingual ketamine

Oral and sublingual ketamine for depression are not addressed and effectively treated as cash-pay.

The medical policy on esketamine nasal spray and IV ketamine does not mention oral or sublingual ketamine products for depression or provide medical necessity criteria for them. Without any supportive policy language, there is no standard path for oral ketamine to be treated as a covered benefit for depressive disorders.

What this means for you:

If you work with a clinic that prescribes oral or sublingual ketamine, you should assume you will be paying the clinic’s cash rate and not relying on your Blue Cross Blue Shield of Massachusetts coverage for the medication or associated visits.

Important fine print for Blue Cross Blue Shield of Massachusetts members

  • This summary is based on Blue Cross Blue Shield of Massachusetts materials including medical policy “Esketamine Nasal Spray (Spravato) and Intravenous Ketamine for Mental Health Conditions (Medical Policy 087)” and the related prior authorization request form.
  • These documents describe how esketamine and IV ketamine requests are evaluated but do not guarantee payment for any specific member, diagnosis, clinic, or claim.
  • Your actual benefits depend on your individual contract, so always review your Evidence of Coverage and call the Member Services number on your ID card before scheduling treatment.
  • Blue Cross Blue Shield of Massachusetts offers multiple products, and employer plans or other arrangements may have ketamine rules that differ from what is summarized here.

Does Blue Cross Blue Shield of Michigan Cover IV, Injection and Oral Ketamine?

NO – Blue Cross Blue Shield of Michigan does not cover IV, injection or oral ketamine.

The medical policy on intravenous anesthetics explains that IV anesthetic infusions such as ketamine for psychiatric disorders, including treatment-resistant depression, are considered investigational and not covered. The policy is written around IV administration and does not create explicit coverage criteria for intramuscular, oral, or sublingual ketamine for depression.

Route Covered for depression? What the policy says*
IV ketamine infusions NO

Classified as investigational and not covered for psychiatric disorders including treatment-resistant depression.
The policy states that intravenous infusion of anesthetics, such as ketamine, for the treatment of psychiatric disorders, including treatment-resistant depression, is considered investigational and therefore not covered.
Injection ketamine (IM / subcutaneous) NOT STATED

Coverage very unlikely; depression language is written only for IV anesthetic infusions.
The policy scope is limited to intravenous administration of anesthetics and does not address intramuscular ketamine for depression, leaving IM and subcutaneous routes without a defined coverage determination.
Oral / sublingual ketamine NOT STATED

Coverage very unlikely; oral and sublingual ketamine are mentioned only in background discussion.
The background section notes that test infusions have been used to assess whether medications such as oral mexiletine or oral ketamine may be effective, but it does not create an explicit coverage decision for oral ketamine in depression.

*Based on Blue Cross Blue Shield of Michigan medical policy “Intravenous Anesthetics for the Treatment of Chronic Pain and Psychiatric Disorders”.

NOT COVERED

IV ketamine infusions

IV ketamine infusions for depression are not covered.

The medical policy explains that intravenous infusion of anesthetics such as ketamine for psychiatric disorders, including but not limited to treatment-resistant depression, is considered investigational. Services labeled investigational in this way are not treated as covered benefits, which places IV ketamine for depression in the non-covered category.

What this means for you:

If you pursue IV ketamine infusions for depression, clinics will almost always treat them as self-pay, and claims sent to your plan are very likely to be denied as investigational and not covered.

NOT STATED

Injection ketamine (IM / subcutaneous)

Coverage for injection ketamine for depression is not stated and in practice functions like a no.

The same policy is framed around IV anesthetic infusions and does not provide a separate coverage determination for intramuscular or subcutaneous ketamine in depression. When IV ketamine is already considered investigational and non-covered for psychiatric indications, clinics generally assume that off-label IM or subcutaneous protocols for depression will be treated the same way.

What this means for you:

If a clinic offers IM or subcutaneous ketamine for depression, you should expect those sessions to be cash-pay and not reimbursed as a standard mental health benefit.

NOT STATED

Oral / sublingual ketamine

Oral and sublingual ketamine for depression are not addressed and effectively treated as cash-pay.

The intravenous anesthetics policy mentions oral ketamine only in background discussion, noting that test infusions have been used to assess whether medications such as oral ketamine may be effective. It does not set medical necessity criteria or a coverage decision for oral or sublingual ketamine in depression.

What this means for you:

If you work with a clinic that prescribes oral or sublingual ketamine, you should assume you will be paying the clinic’s cash rate and not relying on your Blue Cross Blue Shield of Michigan coverage for the medication or associated visits.

Important fine print for Blue Cross Blue Shield of Michigan members

  • This summary is based on Blue Cross Blue Shield of Michigan materials including the medical policy “Intravenous Anesthetics for the Treatment of Chronic Pain and Psychiatric Disorders”, related policy documents such as additional anesthetic policy guidance, and provider communications in the ereferrals news and updates.
  • These materials describe how requests for IV anesthetics such as ketamine are evaluated but do not guarantee payment for any specific member, diagnosis, clinic, or claim.
  • Your actual benefits depend on your individual contract, so always review your Evidence of Coverage and call the Member Services number on your ID card before scheduling treatment.
  • Blue Cross Blue Shield of Michigan offers multiple products, and employer plans or other arrangements may have ketamine rules that differ from what is summarized here.

Does Horizon Blue Cross Blue Shield of New Jersey Cover IV, Injection and Oral Ketamine?

NO – Horizon Blue Cross Blue Shield of New Jersey does not cover IV, injection or oral ketamine.

The medical policy on intravenous anesthetics classifies IV ketamine infusions for psychiatric disorders, including depression, as investigational and therefore not covered. The policy is limited to IV anesthetic infusions and mentions oral ketamine only in background discussion, without creating any coverage pathway for intramuscular, oral, or sublingual ketamine for depression.

Route Covered for depression? What the policy says*
IV ketamine infusions NO

Classified as investigational and not covered for depression.
The policy states that intravenous infusion of anesthetics, such as ketamine, for chronic pain and psychiatric disorders (including depression) is considered investigational, and investigational services are not covered.
Injection ketamine (IM / subcutaneous) NOT STATED

Coverage very unlikely; depression language is written only for IV infusions.
The policy is limited to intravenous anesthetic infusions and does not give any separate coverage determination for intramuscular ketamine for depression, leaving IM and subcutaneous routes without a defined approval pathway.
Oral / sublingual ketamine NOT STATED

Coverage very unlikely; oral ketamine is mentioned only in background discussion.
Background text notes that IV test infusions have been used to assess whether medications such as oral ketamine may be effective, but there is no explicit coverage statement for oral or sublingual ketamine in depression.

*Based on Horizon Blue Cross Blue Shield of New Jersey medical policy “Intravenous Anesthetics for the Management of Chronic Pain and Depression (Policy 035)”.

NOT COVERED

IV ketamine infusions

IV ketamine infusions for depression are not covered.

The policy’s coverage statement explains that intravenous infusion of anesthetics, including ketamine, for chronic pain and psychiatric disorders such as depression is considered investigational. It also clarifies that the plan does not provide coverage for investigational services, which places IV ketamine for depression firmly outside covered mental health benefits.

What this means for you:

If you pursue IV ketamine infusions for depression, clinics will almost always treat them as self-pay, and any claims sent to your plan are very likely to be denied as investigational and not covered.

NOT STATED

Injection ketamine (IM / subcutaneous)

Coverage for injection ketamine for depression is not stated and in practice functions like a no.

The same policy is framed around intravenous anesthetic infusions and does not specifically discuss intramuscular or subcutaneous ketamine for psychiatric indications. When IV ketamine is already considered investigational and non-covered for depression, clinics generally assume that off-label IM or subcutaneous protocols will be treated the same way.

What this means for you:

If a clinic offers IM or subcutaneous ketamine for depression, you should expect those sessions to be cash-pay and not reimbursed as a standard mental health benefit.

NOT STATED

Oral / sublingual ketamine

Oral and sublingual ketamine for depression are not addressed and effectively treated as cash-pay.

In the background discussion, the policy notes that IV test infusions have been used in treatment planning to assess whether oral ketamine may be effective, but it stops short of setting coverage criteria or a medical necessity statement for oral or sublingual ketamine. Without explicit coverage language, there is no standard path for these formulations to be treated as covered benefits for depression.

What this means for you:

If you work with a clinic that prescribes oral or sublingual ketamine, you should assume you will be paying the clinic’s cash rate and not relying on your Horizon Blue Cross Blue Shield of New Jersey coverage for the medication or associated visits.

Important fine print for Horizon Blue Cross Blue Shield of New Jersey members

  • This summary is based on Horizon policies and communications including the medical policy “Intravenous Anesthetics for the Management of Chronic Pain and Depression (Policy 035)”, the online medical policy section view, and the provider news article “Medical policy revision: intravenous anesthetics for the management of chronic pain and depression”.
  • These materials describe how IV anesthetic infusions such as ketamine are evaluated but do not guarantee payment for any specific member, diagnosis, clinic, or claim.
  • Your actual benefits depend on your individual contract, so always review your Evidence of Coverage and call the Member Services number on your ID card before scheduling treatment.
  • Horizon Blue Cross Blue Shield of New Jersey offers multiple products, and employer plans, Medicaid, Medicare, or other arrangements may have ketamine rules that differ from what is summarized here.

Does Independence Blue Cross Cover IV, Injection and Oral Ketamine?

NO – Independence Blue Cross does not cover IV, injection or oral ketamine.

The intravenous ketamine and intranasal esketamine policy classifies IV ketamine for depression as experimental and investigational and therefore not covered outside anesthesia or cancer pain indications. The document focuses on IV Ketalar and Spravato and does not describe any coverage path for intramuscular, oral, or sublingual ketamine for depression.

Route Covered for depression? What the policy says*
IV ketamine infusions NO

Classified as experimental/investigational for depression and not covered outside limited pain indications.
The policy states that ketamine (Ketalar) for the treatment of depression is considered experimental and investigational and therefore not covered, with coverage limited to anesthesia or cancer pain uses.
Injection ketamine (IM / subcutaneous) NOT STATED

Coverage very unlikely; criteria and limitations are written only for IV ketamine.
Policy criteria and limitations are framed around intravenous ketamine infusions, and intramuscular ketamine for depression is not discussed as a covered or medically necessary treatment.
Oral / sublingual ketamine NOT STATED

Coverage very unlikely; oral and sublingual ketamine are not mentioned.
The policy focuses on IV ketamine and intranasal esketamine and does not reference oral or sublingual ketamine for depression, so any request would fall under general off-label rules.

*Based on Independence Blue Cross medical policy “Intravenous Ketamine (Ketalar®) and Intranasal Esketamine (Spravato®) (Policy 08.01.80c)”.

NOT COVERED

IV ketamine infusions

IV ketamine infusions for depression are not covered.

The ketamine policy explains that ketamine (Ketalar) for the treatment of depression is considered experimental and investigational and therefore not covered, while allowing limited use in anesthesia or cancer pain. When a service is classified as experimental or investigational in this way, it is not treated as a covered mental health benefit.

What this means for you:

If you pursue IV ketamine infusions for depression, clinics will almost always treat them as self-pay, and claims sent to your plan are very likely to be denied as experimental and not covered.

NOT STATED

Injection ketamine (IM / subcutaneous)

Coverage for injection ketamine for depression is not stated and functions like a no.

The same policy lays out criteria only for intravenous ketamine and does not create a separate role for intramuscular or subcutaneous ketamine in depression. When IV ketamine for depression is already labeled experimental and not covered, clinics generally assume that off-label IM protocols will be handled the same way.

What this means for you:

If a clinic offers IM or subcutaneous ketamine for depression, you should expect those sessions to be cash-pay and not reimbursed as a standard mental health benefit.

NOT STATED

Oral / sublingual ketamine

Oral and sublingual ketamine for depression are not addressed and effectively treated as cash-pay.

The IV ketamine and intranasal esketamine policy does not mention oral or sublingual ketamine for depression or provide medical necessity criteria for these routes. Without explicit coverage language, there is no standard path for oral ketamine to be treated as a covered benefit for depressive disorders.

What this means for you:

If you work with a clinic that prescribes oral or sublingual ketamine, you should assume you will be paying the clinic’s cash rate and not relying on your Independence Blue Cross coverage for the medication or associated visits.

Important fine print for Independence Blue Cross members

  • This summary is based on Independence Blue Cross and related plan materials, including medical policy “Intravenous Ketamine (Ketalar®) and Intranasal Esketamine (Spravato®) (Policy 08.01.80c)” and the corresponding AmeriHealth commercial policy page.
  • These documents describe how IV ketamine and Spravato requests are evaluated but do not guarantee payment for any specific member, diagnosis, clinic, or claim.
  • Your actual benefits depend on your individual contract, so always review your Evidence of Coverage and call the Member Services number on your ID card before scheduling treatment.
  • Independence Health Group and its affiliated plans may have different rules across products and funding arrangements, and employer, Medicaid, or Medicare plans can apply different ketamine criteria than those summarized here.

Does Humana Cover IV, Injection and Oral Ketamine?

Coverage for IV, injection and oral ketamine is not stated in Humana commercial policies; TRICARE language says ketamine in any form is not covered for depression, so coverage is very unlikely.

The available Humana commercial policy portal does not publish a clear position on IV or other forms of ketamine for depression. In a related Humana Military TRICARE Spravato policy, ketamine administered in any form is explicitly described as not covered for the treatment of depression, which is a strong signal that clinics should not expect routine coverage for IV, injection, oral, or sublingual ketamine through Humana.

Route Covered for depression? What the policy says*
IV ketamine infusions NOT STATED

Coverage very unlikely; TRICARE policy says ketamine in any form is not covered for depression and commercial policies give no IV criteria.
The Humana Military TRICARE Spravato policy states that ketamine, administered in any form, is not covered for the treatment of depression, while the Humana commercial portal does not publish IV ketamine coverage criteria.
Injection ketamine (IM / subcutaneous) NOT STATED

Coverage very unlikely; TRICARE treats ketamine in any form as non-covered for depression and commercial materials are silent on IM use.
Policy sources do not discuss intramuscular ketamine for depression, and the TRICARE document describes ketamine in any form as not covered for this indication, leaving no published path to covered IM treatment.
Oral / sublingual ketamine NOT STATED

Coverage very unlikely; neither commercial nor TRICARE materials support oral or sublingual ketamine for depression.
Policy sources do not discuss oral or sublingual ketamine for depression, and the TRICARE Spravato policy’s statement that ketamine in any form is not covered for depression implies that oral use would be treated as a non-covered, off-label service.

*Based on Humana Military TRICARE Spravato coverage materials, including the document “Spravato (esketamine) nasal spray – TRICARE policy MP22-026E”.

NOT STATED

IV ketamine infusions

IV ketamine infusions for depression are not covered in TRICARE policy and function like a no for Humana commercial coverage.

The TRICARE Spravato policy explains that ketamine, administered in any form, is not covered for the treatment of depression, which includes IV infusions as one of the excluded routes. Humana’s commercial policy portal does not publish its own IV ketamine criteria for depression, so clinics typically read the combination of silence on commercial coverage and explicit TRICARE exclusion as a strong non-coverage signal.

What this means for you:

If you pursue IV ketamine for depression with a Humana-affiliated plan, you should expect clinics to bill you at their cash rate and treat IV infusions as self-pay, unless a clinic can show you a very specific written authorization for your case.

NOT STATED

Injection ketamine (IM / subcutaneous)

Coverage for injection ketamine for depression is not stated and in practice functions like a no.

Humana’s public policy sources do not lay out medical necessity criteria for intramuscular or subcutaneous ketamine in depression. When a related TRICARE policy has already stated that ketamine in any form is not covered for depression, and commercial materials offer no IM carve-out, clinics assume that IM ketamine for depression will not be paid as a covered behavioral health benefit.

What this means for you:

If a clinic offers IM or subcutaneous ketamine for depression, you should plan on paying the clinic’s cash rate and not count on reimbursement from your Humana coverage.

NOT STATED

Oral / sublingual ketamine

Oral and sublingual ketamine for depression are not addressed and effectively treated as cash-pay.

The Humana commercial policy portal and the TRICARE Spravato document do not publish coverage criteria for oral or sublingual ketamine in depression. With no supportive language and a clear TRICARE statement that ketamine in any form is not covered for depression, oral formulations are treated as off-label, self-pay options rather than covered mental health treatments.

What this means for you:

If you work with a clinic that prescribes oral or sublingual ketamine, you should assume you will be paying out of pocket for both the medication and related visits, unless you have explicit written confirmation of coverage for your specific situation.

Important fine print for Humana members

  • This summary is based on Humana policy sources including the Humana Medical and Pharmacy Coverage Policies portal, the Humana Military TRICARE Spravato policy MP22-026E, and the Spravato continued request form at Humana provider resources.
  • These materials describe how ketamine and Spravato requests are evaluated in TRICARE and hint at Humana’s broader approach, but they do not guarantee payment for any specific member, diagnosis, clinic, or claim.
  • Your actual benefits depend on your individual contract, so always review your Evidence of Coverage and call the Member Services number on your ID card before scheduling treatment.
  • Humana offers multiple products, including commercial, military, and other lines of business, and ketamine rules can differ across these products even when they are administered by the same company.

Does Molina Healthcare Cover IV, Injection and Oral Ketamine?

NO – Molina Healthcare does not cover IV, injection or oral ketamine.

The Spravato esketamine nasal spray clinical criteria document lists intravenous ketamine infusions as not FDA approved and not a covered benefit, treating IV ketamine for depression as an experimental or investigational use. The same materials do not create any coverage pathway for intramuscular, oral, or sublingual ketamine for depression, so those routes are effectively treated as non-covered as well.

Route Covered for depression? What the policy says*
IV ketamine infusions NO

Listed as not FDA approved and not a covered benefit.
The clinical criteria state that use of ketamine as an intravenous infusion is not FDA approved and is not a covered benefit, placing IV ketamine for depression under experimental or investigational uses.
Injection ketamine (IM / subcutaneous) NOT STATED

Coverage very unlikely; depression language is written only for IV ketamine infusions.
The Spravato criteria do not specifically address intramuscular ketamine for depression or pain outside the anesthesia context, leaving IM and subcutaneous routes without a defined coverage determination.
Oral / sublingual ketamine NOT STATED

Coverage very unlikely; oral and sublingual ketamine are not mentioned for depression.
The policy materials do not mention oral or sublingual ketamine for depression or pain indications, so there is no published coverage decision for these formulations.

*Based on Molina clinical criteria for Spravato esketamine nasal spray, including the document “Spravato esketamine nasal spray clinical criteria IME-PAM-021” and related Iowa Medicaid materials such as the coverage criteria posted by the state at Iowa HHS pharmacy and medical policy resources.

NOT COVERED

IV ketamine infusions

IV ketamine infusions for depression are not covered.

The Spravato clinical criteria explicitly list use of ketamine as an intravenous infusion as not FDA approved and not a covered benefit, placing IV ketamine for depression under the experimental or investigational category. When a service is labeled this way, it is not treated as a medically necessary covered treatment for depressive disorders.

What this means for you:

If you pursue IV ketamine infusions for depression, clinics will almost always treat them as self-pay, and claims sent to your plan are very likely to be denied as non-covered, experimental treatment.

NOT STATED

Injection ketamine (IM / subcutaneous)

Coverage for injection ketamine for depression is not stated and usually functions like a no.

The same criteria document focuses on IV ketamine exclusions and does not create any separate rules for intramuscular ketamine in depression or chronic pain outside the anesthesia setting. When IV ketamine infusions are already excluded as not a covered benefit, clinics generally assume that off-label IM or subcutaneous protocols for depression will not be covered either.

What this means for you:

If a clinic offers IM or subcutaneous ketamine for depression, you should expect those sessions to be cash-pay and not reimbursed through your standard behavioral health or medical benefits.

NOT STATED

Oral / sublingual ketamine

Oral and sublingual ketamine for depression are not addressed and effectively treated as cash-pay.

The available Molina and state criteria documents do not mention oral or sublingual ketamine as treatment options for depression or related pain indications. Without any medical necessity criteria or benefit language for oral ketamine, there is no standard path for these formulations to be approved as covered services for depressive disorders.

What this means for you:

If you work with a clinic that prescribes oral or sublingual ketamine, you should assume you will be paying the clinic’s cash rate and not relying on your Molina coverage for the medication or associated visits.

Important fine print for Molina Healthcare members

  • This summary is based on Molina and Iowa Medicaid materials, including the Spravato esketamine nasal spray clinical criteria document “Spravato esketamine nasal spray clinical criteria IME-PAM-021” and related coverage criteria posted by Iowa HHS at the state’s pharmacy and medical policy site.
  • These documents describe how Spravato and ketamine-related services are evaluated but do not guarantee payment for any specific member, diagnosis, clinic, or claim.
  • Your actual benefits depend on your individual contract and state program, so always review your Evidence of Coverage or Medicaid member handbook and call the Member Services number on your ID card before scheduling treatment.
  • Molina operates plans in multiple states and program types, and Medicaid, marketplace, or other products may have different ketamine rules than those summarized here.

Does Point32Health (Harvard Pilgrim & Tufts Health Plan) Cover IV, Injection and Oral Ketamine?

Coverage for IV, injection and oral ketamine is not stated in Point32Health publicly available policies; coverage is very unlikely.

No publicly available Point32Health policy has been found that clearly states whether IV, intramuscular, oral, or sublingual ketamine for depression is covered or excluded. The available Spravato medical necessity guideline focuses on intranasal esketamine and does not address other ketamine formulations or routes for depression.

Route Covered for depression? What the policy says*
IV ketamine infusions NOT STATED

Coverage very unlikely; no publicly available policy found addressing IV ketamine for depression.
No publicly available Point32Health policy found that clearly states whether IV ketamine for depression is covered or excluded.
Injection ketamine (IM / subcutaneous) NOT STATED

Coverage very unlikely; no publicly available policy found addressing IM ketamine for depression.
No publicly available Point32Health policy found that clearly states whether intramuscular ketamine for depression is covered or excluded.
Oral / sublingual ketamine NOT STATED

Coverage very unlikely; no publicly available policy found addressing oral ketamine for depression.
No publicly available Point32Health policy found that clearly states whether oral or sublingual ketamine for depression is covered or excluded.

*Based on available Point32Health policy materials including the Spravato medical necessity guideline.

NOT STATED

IV ketamine infusions

IV ketamine coverage for depression is not stated in publicly available policies.

Point32Health (the parent company of Harvard Pilgrim and Tufts Health Plan) does not publish a clear medical policy on IV ketamine for depression. The available Spravato guideline addresses only intranasal esketamine and does not create coverage criteria for IV ketamine infusions.

What this means for you:

If you pursue IV ketamine for depression with a Point32Health plan, you should expect clinics to treat it as self-pay unless you can obtain clear written confirmation of coverage for your specific situation.

NOT STATED

Injection ketamine (IM / subcutaneous)

Injection ketamine coverage for depression is not stated in publicly available policies.

Available policy materials do not address intramuscular or subcutaneous ketamine for depression. Without published coverage criteria or medical necessity language for IM ketamine, clinics typically treat these protocols as non-covered services.

What this means for you:

If a clinic offers IM or subcutaneous ketamine for depression, you should plan on paying the clinic’s cash rate unless you receive explicit written confirmation that your plan will cover these sessions.

NOT STATED

Oral / sublingual ketamine

Oral and sublingual ketamine coverage for depression is not stated in publicly available policies.

Point32Health’s available policy documents do not mention oral or sublingual ketamine for depression. Without any medical necessity criteria or coverage determination for these formulations, there is no clear path for oral ketamine to be treated as a covered benefit.

What this means for you:

If you work with a clinic that prescribes oral or sublingual ketamine, you should assume you will be paying out of pocket unless you obtain very specific written confirmation of coverage for your case.

Important fine print for Point32Health members

  • This summary is based on available Point32Health policy materials including the Spravato medical necessity guideline.
  • Point32Health operates Harvard Pilgrim Health Care and Tufts Health Plan, and publicly available policy materials may not reflect all internal coverage determinations for ketamine services.
  • Your actual benefits depend on your individual contract, so always review your Evidence of Coverage and call the Member Services number on your ID card before scheduling treatment.
  • Point32Health offers multiple products across different markets, and coverage rules may vary significantly between plan types and employer groups.

Does BlueCross BlueShield of Tennessee Cover IV, Injection and Oral Ketamine?

NO – BlueCross BlueShield of Tennessee does not cover IV, injection or oral ketamine.

The medical policy on intravenous anesthetics lists intravenous ketamine for treatment-resistant depression and other psychiatric disorders as investigational and not covered. The policy focuses on IV administration and does not create explicit coverage criteria for intramuscular, oral, or sublingual ketamine for depression.

Route Covered for depression? What the policy says*
IV ketamine infusions NO

Classified as investigational and not covered for treatment-resistant depression and other psychiatric disorders.
Policy lists intravenous ketamine for treatment resistant depression and other psychiatric disorders as investigational and not covered.
Injection ketamine (IM / subcutaneous) NOT STATED

Coverage very unlikely; policy language is written only for IV anesthetics.
No intramuscular ketamine specific language for depression in medical policy manuals located.
Oral / sublingual ketamine NOT STATED

Coverage very unlikely; oral and sublingual ketamine are not mentioned in policy materials.
No oral or sublingual ketamine specific language for depression in medical policy manuals located.

*Based on BlueCross BlueShield of Tennessee medical policy “Intravenous Anesthetics for the Treatment of Chronic Pain”.

NOT COVERED

IV ketamine infusions

IV ketamine infusions for depression are not covered.

The intravenous anesthetics policy specifically lists intravenous ketamine for treatment-resistant depression and other psychiatric disorders as investigational. When a service is classified as investigational in this way, it is not treated as a covered benefit for depressive disorders.

What this means for you:

If you pursue IV ketamine infusions for depression, clinics will almost always treat them as self-pay, and claims sent to your plan are very likely to be denied as investigational and not covered.

NOT STATED

Injection ketamine (IM / subcutaneous)

Coverage for injection ketamine for depression is not stated and functions like a no.

The medical policy manual does not include specific language addressing intramuscular or subcutaneous ketamine for depression. When IV ketamine is already classified as investigational and non-covered for psychiatric disorders, clinics generally assume that off-label IM or subcutaneous protocols will be treated the same way.

What this means for you:

If a clinic offers IM or subcutaneous ketamine for depression, you should expect those sessions to be cash-pay and not reimbursed as a standard mental health benefit.

NOT STATED

Oral / sublingual ketamine

Oral and sublingual ketamine for depression are not addressed and effectively treated as cash-pay.

The available medical policy materials do not mention oral or sublingual ketamine for depression. Without any supportive policy language or medical necessity criteria, there is no standard path for these formulations to be treated as covered benefits for depressive disorders.

What this means for you:

If you work with a clinic that prescribes oral or sublingual ketamine, you should assume you will be paying the clinic’s cash rate and not relying on your BlueCross BlueShield of Tennessee coverage for the medication or associated visits.

Important fine print for BlueCross BlueShield of Tennessee members

  • This summary is based on BlueCross BlueShield of Tennessee materials including the medical policy “Intravenous Anesthetics for the Treatment of Chronic Pain” and related resources at Caremark pharmacy information and BCBST behavioral health provider resources.
  • These materials describe how IV ketamine requests are evaluated but do not guarantee payment for any specific member, diagnosis, clinic, or claim.
  • Your actual benefits depend on your individual contract, so always review your Evidence of Coverage and call the Member Services number on your ID card before scheduling treatment.
  • BlueCross BlueShield of Tennessee offers multiple products, and employer plans or other arrangements may have different ketamine rules than those summarized here.

Frequently Asked Questions About Insurance Coverage of IV, Injection & Oral Ketamine

These answers are based on public policy documents from 18 major commercial insurers and focus on ketamine used to treat depression, not anesthesia or pain.

?

Do any insurance companies actually cover IV ketamine for depression?

Yes – but it’s rare and heavily restricted. In the table on this page, only 3 out of 18 major commercial insurers have a pathway on paper to cover IV ketamine for depression.

Even those require strict prior authorization and very specific criteria (usually treatment-resistant depression with multiple failed antidepressants and in-clinic monitoring). Coverage is never automatic and can vary by state, employer, and plan. For everyone else in the table, IV ketamine is treated as “experimental” or “not medically necessary,” which is insurer-speak for “we don’t cover this.”

0%

If my plan says “NO” to IV ketamine, what are the chances it covers injection or oral ketamine instead?

Realistically, close to zero. When an insurer has gone on record saying no to IV ketamine for depression, that usually means it has decided ketamine as a depression treatment is experimental or not medically necessary.

IV is the most medicalized route (monitored, in-clinic, dosing protocols). If they won’t pay for that, they are not secretly covering intramuscular shots or compounded lozenges on the side.

In this table, “NO*” is there to flag that injection or oral ketamine is functionally a no, even if the policy doesn’t literally spell out the word “no” for that route.

NS

My insurer is listed as “Not Stated.” Does that mean I might have a better chance of getting coverage?

Unfortunately, “Not Stated” usually behaves like “no coverage by default.” It only means there was no clear sentence in a public policy document that we could quote for that route.

It does not mean the insurer is on the fence or leaning toward yes. In practice, when a plan is silent about IV, injection, or oral ketamine for depression:

  • There’s no defined benefit you can point to, and
  • Clinics almost always treat that route as self-pay unless they get a very unusual one-off approval.

If your insurer is “Not Stated” for a route, the safe assumption is: “assume no unless you have a written yes for your specific plan.”

S

Why do insurers refuse IV, injection, and oral ketamine but still cover Spravato (esketamine nasal spray) more often?

Because they see them as two different worlds:

  • IV, injection, and oral ketamine for depression are off-label uses of a generic anesthetic. Most insurers lump them into their “experimental / investigational” bucket and deny coverage.
  • Spravato® (esketamine nasal spray) is an FDA-approved product for treatment-resistant depression, with a REMS program, specific dosing rules, and its own billing codes. That gives insurers a cleaner way to say, “We’ll cover this if you meet our criteria.”

So it’s common to see an insurer say no to IV / injection / oral ketamine while saying “yes, under strict rules” to Spravato in a separate policy.

Ketamine Therapy for Depression logo

Copyright © 2025 · All Rights Reserved
  • Contact Us
  • About Us
  • Press
  • Editorial Policy
  • Privacy Policy
  • Terms of Use
  • Research Resource Hub
  • Medical Review Policy
Most Important Pages
  • → Start Your Journey
  • → IV, Shots or Nasal Spray?
  • → How Much Does Ketamine Therapy Cost?
  • → How Many Sessions Will You Need?
  • → Research on Ketamine’s Effectiveness
  • → Spravato Insurance Calculator Costs
  • → Free Rides To Medical Appointments
  • → Increase Your Chances of Remission
Official Profiles
  • YouTube
  • X (Twitter)
  • Instagram
  • Reddit
  • Substack
  • LinkedIn
  • TikTok
  • Medium
  • Quora
Research Profiles
  • ORCID
  • OSF
  • Figshare
  • SSRN
  • Zenodo
  • Google Scholar
  • Wikidata (Person)
  • Wikidata (Organization)

Medical Disclaimer: This site provides educational information only and is not a substitute for professional medical advice. If you are in crisis or thinking of suicide, call or text 988 in the U.S. or find your local emergency number.